<DOC>
	<DOC>NCT02655692</DOC>
	<brief_summary>The purpose of this study is to test the safety and efficacy of repeated doses of ketamine as compared to placebo, in reducing symptoms of Posttraumatic Stress Disorder (PTSD) in an active duty military and Veteran population.</brief_summary>
	<brief_title>CAP-Ketamine for Antidepressant Resistant PTSD</brief_title>
	<detailed_description>In this 2-site clinical trial, intended to evaluate the safety and efficacy of repeated doses of ketamine for treatment resistant PTSD, Veterans and active duty military personnel who meet criteria for PTSD and the additional inclusion and exclusion criteria will be randomized to one of three treatment arms (placebo, low dose ketamine, high dose ketamine). Participants receive the study drug via intravenous infusion twice per week for 4-weeks.</detailed_description>
	<mesh_term>Stress Disorders, Post-Traumatic</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>male or female Veterans or active duty military personnel between the ages of 18 and 70 years diagnosis of PTSD history of trialing one or more antidepressant medications with little to no PTSD symptom improvement ability to provide written informed consent females who are currently pregnant or breastfeeding current risk for suicide history of severe head injury</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PTSD</keyword>
	<keyword>Ketamine</keyword>
	<keyword>Veteran</keyword>
	<keyword>Military</keyword>
	<keyword>Clinical Trial</keyword>
</DOC>